Ensysce is listed on NASDAQ and received FDA Orphan Drug Designation for its CRPS therapy.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ensysce is listed on NASDAQ and received FDA Orphan Drug Designation for its CRPS therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Ensysce Biosciences, listed on Nasdaq, acquired Cy Biopharma, and representatives presented at a public FDA hearing.Sub-event
Ensysce listed on Nasdaq and received FDA Orphan Drug Designation for CRPS therapy.1 source
Keep exploring
The entities involved
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Entrada Therapeutics and Pluri are identified as small-cap healthcare companies listed on the Nasdaq stock exchange.
- Decoy Therapeutics was listed on the Nasdaq stock exchange on September 22, 2026.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.